BOSTON, MA, UNITED STATES, August 10, 2026 /EINPresswire.com/ -- Bios Life, an AI-native cancer surveillance company, today emerges from stealth with $25 million in seed financing to build a more personalized and continuous approach to cancer screening and survivorship care. The seed round was led by Redmile, Vsquared Ventures and Kindred Capital, supported by a syndicate of leading healthcare and technology investors across the United States and Europe.

Bios Life is developing a personalized surveillance strategy to support high-risk individuals and cancer survivors that evolves with them over time. More than 40 million people in the US are at heightened risk for cancer or are cancer survivors, two large and underserved groups that often face fragmented and reactive care. Meanwhile more than 40% of people will be diagnosed with cancer in their lifetime, and of those more than 30% will be diagnosed at stage 3 or 4. Bios Life is creating a predictive care platform that targets these overlooked high-risk groups, bringing together advanced multi-modality foundation models and direct patient care to serve individuals across the US. At the same time the company is announcing a multi-year strategic alliance with Tempus, a leader in AI-driven precision medicine, to help train and validate its predictive models.

Ryan Richardson, Co-founder and CEO, Bios Life: "Tens of millions of high-risk individuals and cancer survivors lack access to cutting-edge care which is tailored to their particular needs and their unique biology. Bios Life is building a novel technology portfolio and specialized care delivery model to uniquely serve these individuals at a level that has not been possible until now – one that is deeply personalized and delivered at scale. The support of world-class partners and investors at launch gives us the foundation to become a category-defining company in this emerging space."

A New Category of Cancer Care

Bios Life aims to fundamentally redesign care for cancer survivors and those at elevated risk by delivering continuous, personalized, technology-enabled surveillance directly to patients - and in partnership with leading cancer centers - via its virtual care delivery platform with licensed care teams across the United States. Bios Life’s platform launches in the US in the second half of 2026 and consumers can join the waitlist now: www.bioslife.ai.

Kevin Oeffinger, MD – Director of the Duke Cancer Institute Center for Onco-Primary Care: "Cancer screening and surveillance have been at a relative standstill for the past 20-30 years. The vast majority of individuals at elevated risk of cancer are not screened according to standard-of-care guidelines, and one out of every five newly diagnosed cancers in the US is found in cancer survivors. The AI-enhanced virtual model developed by Bios Life has the potential to greatly enhance the delivery of care to these high-risk populations; this is a game changer. Utilizing AI tools with a genetic and lifestyle backbone will move us from stagnation to the long-promised potential of personalized and precise cancer screening."

Personalized Care, Powered by Advanced Genomic AI

Through its cutting-edge AI technology platforms and end-to-end care delivery platform, Bios Life enables the delivery of cancer surveillance and holistic supportive care tailored to each individual’s unique needs. The result is a digital twin for every patient—a continuously updated model of their biology that moves away from disjointed one-time screening episodes towards integrated lifetime surveillance. At the core of Bios Life’s platform is a suite of proprietary technologies, including its Personalized Cancer Risk and Cancer Surveillance Platforms. The company also holds commercial rights to the Nucleotide Transformer genomics foundation model developed by BioNTech-InstaDeep, among the most cited and most downloaded AI models for genomics worldwide, which is able to interpret genomic signals at a single-nucleotide resolution. This includes the ability to assess the impact of genetic variation across the genome, including rare and previously uncharacterized variants.

Tempus Alliance

Bios Life has entered a multi-year strategic alliance with Tempus, a leader in AI-driven precision medicine. The agreement allows Bios Life to leverage Tempus’ de-identified multi-modal oncology datasets to train, validate, and deploy powerful predictive models across a wide range of highly prevalent cancers — moving diagnosis and surveillance from reactive scans to continuous, predictive modeling. In addition, through a collaboration with hereditary cancer testing leader Ambry Genetics, now a Tempus company, Bios Life will integrate genetic screening into its preventive platform alongside physician-ordered genetic testing within its survivorship program.

Ryan Fukushima, CEO of Data and Apps, Tempus: “At Tempus, we believe the future of cancer care isn’t just better treatments, it needs better prediction. Our collaboration with Bios Life is an opportunity to rethink how we identify, monitor and support individuals at elevated risk for cancer over the course of their lives. By bringing together Tempus’ multi-modal data platform, Ambry’s expertise in hereditary genetics, and Bios Life’s virtual-first care model, we can move beyond episodic screening toward a more continuous understanding of risk. The goal is simple but ambitious: support high-risk individuals and cancer survivors with a personalized surveillance strategy that evolves with them over time.”
Founding Team with Deep Oncology and Health Technology Experience

Bios Life is led by Co-founder & Chief Executive Officer, Ryan Richardson, the former Chief Strategy Officer of BioNTech and former Chairman of InstaDeep, BioNTech’s wholly owned AI technology company. He is joined by Co-founder and Chief Operating & Business Officer, Zach Taylor, a biotech industry veteran and former Senior Vice President of BioNTech, and Co-founder and Chief Medical Officer, Logan Frank, MD, a board-certified radiologist and former Director of Breast Radiology at the University of Missouri. The management team includes technology leaders Geoff Hyde, Head of Product and Engineering, formerly a technology leader at One Medical and Galileo, and Thomas Pierrot, PhD, Head of Artificial Intelligence, who previously headed the Genomics AI research program at InstaDeep. They are supported by a nationally recognized group of advisors and leaders in cancer diagnostics, artificial intelligence, and cancer screening and survivorship.

Join the waitlist for early access at www.bioslife.ai.

Alina Grant
Burlington PR
email us here